Cash Flow Statement (Annual)
UVE / Universal Insurance Holdings, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities Continuing Operations|
|Net Cash Provided By Used In Operating Activities Continuing Operations||-||-||-||142,506||156,959||123,346||219,271||121,396||245,010|
|Net Cash Provided By Used In Investing Activities Continuing Operations|
|Proceeds From Sale Of Other Property Plant And Equipment||-||-||-||28||8||84||86||36||23|
|Payments To Acquire Property Plant And Equipment||762||1,714||2,395||2,726||1,350||9,267||11,869||8,223||4,618|
|Payments To Acquire Available For Sale Securities Equity||206,054||80,730||-||-||77,859||116,541||65,038||66,688||89,302|
|Payments To Acquire Available For Sale Securities Debt||325,674||129,141||-||-||305,330||106,885||178,198||320,131||180,604|
|Payments To Acquire Real Estate Held For Investment||-||-||-||-||-||-||6,220||5,496||7,218|
|Proceeds From Sale Of Available For Sale Securities Equity||147,635||70,681||-||-||15,542||163,981||41,456||60,558||77,640|
|Proceeds From Sale Of Available For Sale Securities Debt||299,033||116,238||-||-||-||17,153||38,379||86,018||26,179|
|Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities||-||-||-||-||16,306||24,287||74,390||54,615||97,191|
|Net Cash Provided By Used In Investing Activities Continuing Operations||-||-||-||-2,698||-352,683||-77,188||-83,052||-174,311||-85,709|
|Net Cash Provided By Used In Financing Activities Continuing Operations|
|Payments Of Dividends Preferred Stock And Preference Stock||27||20||20||287||29||13||10||10||10|
|Payments Of Dividends Common Stock||20,313||12,533||12,750||18,669||17,725||19,240||22,287||24,192||24,001|
|Payments For Repurchase Of Common Stock||-||-||-||-||32,366||29,736||18,649||8,510||18,141|
|Payments Related To Tax Withholding For Share Based Compensation||223||4,292||172||121||3,161||17,655||12,141||5,451||7,223|
|Repayments Of Debt||368||1,471||1,471||1,471||1,471||7,471||8,470||2,136||2,170|
|Net Cash Provided By Used In Financing Activities Continuing Operations||-||-||-||-22,101||-34,393||-48,036||-54,602||-38,369||-51,545|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect||-||-||-||-||-||-||-||-||-|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents||-||-||-||-||-||-||-||-||-|
Peers - Fire, Marine, and Casualty Insurance (6331)
AFG / American Financial Group, Inc.
AFGE / American Financial Group, Inc.
AFGH / American Financial Group, Inc.
AFW / American Financial Group, Inc.
BCRH / Blue Capital Reinsurance Holdings Ltd.
BRK.A / Berkshire Hathaway, Inc.
BRK.B / Berkshire Hathaway, Inc.
CB / Chubb Ltd
ENH / Endurance Specialty Holdings, Ltd.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET